Page 136 - ebook HCC

GENEVA, SWITZERLANDA, SWITZERLAND
PROGRAMME AND ABSTRACTSAND ABSTRACTS
EASL HCC SUMMITHCC SUMMIT
135
134
134 PROGRAMME GENEV EASL 135
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number B29
TGF B1 AS SERUM BIOMARKER OF
HEPATOCELLULAR CARCINOMA

Amila Mehmedovic , Rusmir Mesihovic , Zora Vukobrat-Bijedić , Nenad Vanis 1
1
2
1
1 Department of hepatology, Clinical Centre University of Sarajevo, Clinic for
2
gastroenterology and hepatology, Sarajevo, Bosnia and Herzegovina
Corresponding author’s e-mail: amila.redzepovic@gmail.com
Introduction: The hepatocellular carcinoma (HCC) is one of the most common malignant
tumors and carries a poor survival rate. Increased understanding of cancer biology and
technological advances have enabled identification of a multitude of pathological, genetic,
and molecular events that drive hepatocarcinogenesis leading to discovery of numerous
potential biomarkers in this disease. The transforming growth factor-beta (TGF-β) cytokine
and its isoforms initiate a signaling cascade which is closely linked to liver fibrosis, cirrhosis
and subsequent progression to HCC.
Aims: The analysis of serum levels of TGF-β1 in HCC patients, according to BCLC scoring
BASIC POSTER ABSTRACTS Methodology: Total of 150 subjects were divided into four groups, depending on the stage Conclusions: Results suggests that differences in the levels of serum concentrations of BASIC POSTER ABSTRACTS
system has been performed, to evaluate its role as biomarker.

of HCC (BCLC scoring system).Group 1:early stage;group 2: intermediate stage; group
TGF ß1 can be used as biomarkers for staging and monitoring the progression of HCC, as
3: advanced stage;group 4: terminal stage), and the control group.The analysis included
well as potential targets of therapy in stages B and C (according to BCLC scoring system).
serum levels of cytokine TGF-β1. Used statistical methods: discriminant multivariate
analysis, ANOVA test, multiple correlation test and Student’s t-test for independent
samples. Charlson comorbidity index was determined for any possible influence of other
2 : Intermediate stage – B; group 3: advanced stage – C; group 4: terminal stage –D), and
comorbid conditions. BCLC (the Barcelona Clinic Liver Cancer) scoring system: group 1: Early stage –A; group
control group (healthy subjects).
Results: The highest mean concentration of this cytokine was in group 3 (advanced
stage of HCC): 1023,55 pg/ml. ANOVA analysis proves that serum levels of TGF-β1 in the
control group differed with respect to the other as follows: in relation to group 1 at the level
of statistical significance p = 0.0028 (F =143.67); in relation to a group of 2 to p =0.0001
level (F = 230.23); in relation to group 3 at p <0.0001 (F = 2584).
By Student’s T test, TGF-b1 in group 1 was significantly different in comparison to group 3
at the level of significance p <0.0001; groups 1 vs.2 at level p <0.0001; 1 vs. 4 at level p =
0.003.Using Factor Analysis, significant stratification of predictive parameters in relation
to the cytokine TGF-β1 was made:1. Age (negative), 2. MELD score (negative), 3. Child-
Pugh (negative), 4.hystory of receiving transfusions, 5. IL-1 (negative), 6. fibrinogen..
The histogram 1 presents the average concentration of TGF-β1 in groups.